Vident Advisory, LLC Neurocrine Biosciences Inc Transaction History

Vident Advisory, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $12.5 Million - $13.6 Million	-95,141 Reduced 97.33%	2,613 $360 Million
Q1 2024 May 14, 2024	BUY	$130.4 - $143.74 $12.4 Million - $13.7 Million	95,219 Added 3756.17%	97,754 $13.5 Billion
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $16,122 - $20,179	-152 Reduced 5.66%	2,535 $334 Million
Q3 2023 Feb 21, 2024	BUY	$94.02 - $117.1 $14,291 - $17,799	152 Added 6.0%	2,687 $302 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $252,631 - $314,647	2,687 New	2,687 $302 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Advisory, LLC with notifications on news.